Low Anti-Tumor Necrosis Factor Levels During Maintenance Phase Are Associated With Treatment Failure in Children With Crohn’s Disease

LD-MTX combination was not associated with higher drug levels, but higher drug levels were associated with reduced risk of treatment failure. Among patients with therapeutic drug levels, we observed no benefit of LD-MTX for patients treated with infliximab. A nonsignificant trend towards reduced treatment failure with the addition of LD-MTX patients treated with adalimumab warrants further investigation.

Authors

Institutions

Publication Details

Journal
Inflammatory Bowel Diseases
Published
2024-10-17
DOI
https://doi.org/10.1093/ibd/izae239
Citations
3
Primary Topic
Inflammatory Bowel Disease
Type
article
Field-Weighted Citation Impact
1.65

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Low Anti-Tumor Necrosis Factor Levels During Maintenance Phase Are Associated With Treatment Failure in Children With Crohn’s Disease

Rana Ammoury, Jeanne Tung, Lourdes Osaba, Traci Jester et al.
3 citations
Inflammatory Bowel Diseases
Inflammatory Bowel Disease
1.65
article

Low Anti-Tumor Necrosis Factor Levels During Maintenance Phase Are Associated With Treatment Failure in Children With Crohn’s Disease

Rana Ammoury, Jeanne Tung, Lourdes Osaba, Traci Jester, Jillian S. Sullivan, Michael D. Kappelman, Ann M. Firestine, Charles M. Samson, Jennifer Strople, Steven J. Steiner, Jonathan Moses, Mark Kusek, Kelly Sandberg, Jill M Dorsey, Dinesh S. Pashankar, Brendan M. Boyle, Jess L. Kaplan, Anastasia Ivanova, Prateek Wali, Ian Leibowitz, Kelly Olano, Monique Bastidas, Ajay Gulati, Peter A. Margolis, Shehzad A. Saeed, Phillip Minar, Athos Bousvaros, Jeremy Adler, Dawn R. Ebach, David A. Wohl, Julie Bass, Pablo J. Palomo, Barbara Joanna Niklinska-Schirtz, Tiffany Linville, Joseph A. Galanko, Hans Herfarth, Keith Benkov, Lisa Pitch, Kelly Chun, José M Cabrera, M Zikry, Dorsey M. Bass, Zarela Molle-Rios
article en
3 citations

Abstract

LD-MTX combination was not associated with higher drug levels, but higher drug levels were associated with reduced risk of treatment failure. Among patients with therapeutic drug levels, we observed no benefit of LD-MTX for patients treated with infliximab. A nonsignificant trend towards reduced treatment failure with the addition of LD-MTX patients treated with adalimumab warrants further investigation.

Inflammatory Bowel DiseasesVol. 31(7)
University of North Carolina at Chapel Hill (US), Children's Hospital of Wisconsin (US), University of Iowa (US), Cincinnati Children's Hospital Medical Center (US), Boston Children's Hospital (US), Lurie Children's Hospital (US), Nationwide Children's Hospital (US), Children's Mercy Hospital (US), Children's National (US), Harvard University (US), Emory University (US), George Washington University (US), Wright State University (US), SUNY Upstate Medical University (US), Medical College of Wisconsin (US), Washington University in St. Louis (US), University of Michigan (US), LabCorp (United States) (US), University of Alabama at Birmingham (US), Yale University (US), Massachusetts General Hospital (US), University of Vermont Children’s Hospital (US), Dayton Children's Hospital (US), Grifols (Spain) (ES), Levine Children's Hospital (US), Stanford Medicine (US), Children's Hospital of The King's Daughters (US), Children's Healthcare of Atlanta (US), C. S. Mott Children's Hospital (US), Nemours Children's Clinic (US), Indiana University School of Medicine, Indiana University – Purdue University Indianapolis (US), University of Nebraska Medical Center (US), University of Cincinnati (US), University of Oklahoma (US), Icahn School of Medicine at Mount Sinai (US)
Patient-Centered Outcomes Research Institute, Leona M. and Harry B. Helmsley Charitable Trust
Good health and well-being
Openalex Percentile: Top 14%
Inflammatory Bowel Disease
1.65
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.